Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

INTRODUCTION: For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously tre...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Thorac Oncol
Huvudupphovsmän: Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050700/
https://ncbi.nlm.nih.gov/pubmed/30316010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.10.003
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk